The New York City-based biopharmaceutical firm develops immunotherapies for infectious diseases and cancer based on its proprietary arenavirus platform, designed to reprogram the body's immune system.
Lead infectious disease candidate is Phase 2-stage HB-101 in cytomegalovirus (CMV)-negative patients waiting for kidney transplants from CMV-positive donors. It is collaborating with Gilead Sciences (NASDAQ:GILD) to accelerate a pipeline of additional infectious disease programs, including hepatitis B and HIV.
2018 Financials ($M): Licensing Revenue: 7.6; Operating Expenses: 28.8 (+102.8%); Net Loss: (16.2) (-27.6%); Cash Consumption: (15.0) (-26.1%).
Subscribe for full text news in your inbox